HEMEL HEMPSTEAD, England, September 9, 2015 /PRNewswire/ --
EUSA Pharma (EUSA), a recently-established specialty pharmaceutical company with global reach, today announced the appointment of William W Crouse to its Board of Directors.
Mr Crouse brings to EUSA 50 years' experience of the life sciences industry. In his most recent role he was a General Partner at Healthcare Ventures, one of the world's largest venture capital firms specializing in biotechnology. In addition to his 20 years' venture capital experience, he spent 30 years in the pharmaceutical and diagnostics industry, holding roles in general management, international operations, strategic planning, licensing, acquisitions, new product development and sales and marketing. Prior to joining HealthCare Ventures, he was Worldwide President of Ortho Diagnostic Systems and a Vice President of Johnson & Johnson International.
He currently serves on the Board of The Medicines Company (NASDAQ: MDCO), and is a Director of three private biotechnology companies. He is also a Trustee and Executive Committee Member of the New York Blood Center and is a member of Lehigh University's Business Advisory Board. He holds a BS in Finance and Economics from Lehigh University and an MBA from Pace University.
"We are delighted to welcome Bill to EUSA Pharma at this exciting time for the company," said Bryan Morton, EUSA Pharma's Executive Chairman ."We have great ambitions for EUSA, and plan to grow our existing profitable business through acquisition and in-licensing. Bill's extensive experience and strategic insight will be a huge asset as we transform our business into a leading transatlantic specialty commercialization company."
"It's an honor to join EUSA, and to help this ambitious company become a major force in the specialty field," said William W Crouse ."Having worked with Bryan and many of the EUSA team previously, I am confident the company has the capabilities and infrastructure in place to rapidly become a leading player in the sector."
About EUSA Pharma
Founded in March 2015, EUSA Pharma is a profitable specialty pharmaceutical company. The company has commercial operations in the US and Europe, and a wider distribution network in approximately 40 countries around the world. Currently, EUSA has a portfolio of five approved and several named-patient specialty hospital products, and the company has ambitious plans to expand this through acquisition and in-licensing. EUSA is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies, and is supported by significant funding raised from leading life science investor Essex Woodlands.
EUSA Pharma's products include: Caphosol® for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy; Collatamp®, a surgical implant impregnated with the antibiotic gentamicin for the treatment and prevention of post-surgical acquired infection; Custodiol® solution for use in the preservation of organs for transplantation; Fomepizole® for the treatment of ethylene glycol poisoning; and Xenazine® for the treatment of movement disorders associated with Huntington's chorea.
For more information please visit http://www.eusapharma.com.
SOURCE EUSA Pharma